In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of health policy at the Leonard D. Schaeffer Center for Health Policy & Economics ...

Eli Lilly and Company is unveiling its new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, which will be available ...

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Tom Dorsett, CEO, RazorMetrics, ...

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Tom Dorsett, CEO, RazorMetrics, comments on why he believes polypharmacy is an overlooked driver of unnecessary ...

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of ...

Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, discusses some of the other specific ...

Trade & Channel Strategies conference explores the frontline issues related to strategy, distribution, and reimbursement—while digging into creative solutions to solve them.

Leaders with top third-party logistics providers discuss the evolving landscape for the sector in 2025—and the new strides made in their quest to help transform the pharma supply chain. Third-party ...

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, describes why these pharma supply chain stakeholders are ...